Modality
Nanobody
MOA
BTKi
Target
PD-L1
Pathway
Angiogenesis
FTDSMA
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
~Feb 2020
→ ~May 2021
Phase 2
Aug 2021
→ Jan 2025
Phase 2Current
NCT03551535
243 pts·SMA
2021-08→2025-01·Terminated
243 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-01-211.2y agoPh3 Readout· SMA
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
P2/3
Termina…
Catalysts
Ph3 Readout
2025-01-21 · 1.2y ago
SMA
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03551535 | Phase 2/3 | SMA | Terminated | 243 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| BAY-3684 | Bayer | Approved | PD-L1 |